OncoMatch/Clinical Trials/NCT05798793
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
Is NCT05798793 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Camrelizumab plus TP and TP for oral squamous cell carcinoma.
Treatment: Camrelizumab plus TP · TP — The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced oral squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1-2N1-2M0, T3-4AN0-2M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: cancer therapy (surgery, chemotherapy, radiotherapy, molecular targeted therapy)
History of other treatments for cancer, including surgery, chemotherapy, radiotherapy or molecular targeted therapy within past 5 years
Cannot have received: anti-PD-1/PD-L1/PD-L2/CTLA-4 or other antibody targeting T cell co-regulatory pathways
Previous therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other antibody targeting T cell co-regulatory pathways
Lab requirements
Blood counts
leukocyte count ≥ 2,000/mm3; absolute neutrophil count ≥ 1,000/mm3; platelet count ≥ 100,000/mm3; hemoglobin ≥ 90 g/l; serum albumin ≥30 g/l; prothrombin time-international normalized ratio ≤ 1.5; inr/pt≤ 1.5; tsh ≤ uln
Kidney function
serum creatinine ≤ 1.5 × uln
Liver function
total bilirubin ≤ 1.5 × uln; ast (sgot) and alt (sgpt) < 2.5 × uln; alp ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05798793 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1-2N1-2M0 or T3-4AN0-2M0 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages